Current Issue

Sponsored
Keywords

Obesity - Related Content

On the Menu: Supersized Soda Wars
March 25, 2013
The NYC ruling halting the ban on large-sized sugary beverages is unlikely to stop future court fights over anti-obesity laws.
7 Biotech Trends for the Coming Year
January 7, 2013
What does 2013 hold for the industry?
Obesity Drug Developers Post Steady Gains
September 6, 2012
High clinical trial costs and slower FDA approvals are among the hurdles to obesity drug approval.
This Time Last Year: Diagnostic Deals, mAb Therapeutics, and Obesity Drug Development
June 1, 2012
Among big news was Roche’s companion diagnostic alliance with Clovis, a melanoma deal with BMS, and FDA’s Avastin decision.
Regulatory Environment Warms Up to Obesity Drugs and Could Heat Up Market
March 20, 2012
With Vivus receiving a positive recommendation, analysts see CV risk as one that can be evaluated post-approval.

ANTIBODY FIGHTS FAT
- Interview with Kim Janda, Ph.D., Ely R. Callaway, Jr. Professor of Chemistry, Member of The Skaggs Institute for Chemical Biology, and Director of the Worm Institute of Research and Medicine, Scripps Research Institute
LINKING CHANGES IN GENE NETWORKS TO DISEASE
- Interview with Eric Schadt, Ph.D., Executive Scientific Director of Research Genetics for Rosetta Inpharmatics, Inc., a wholly-owned subsidiary of Merck & Co.